BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2020 financial results on Monday, August 3, 2020, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2020 Earnings Webcast” hyperlink in the

FDA requested a confirmatory laboratory-based in-use and compatibility study before enrolling new patients Currently-enrolled patients may continue to receive PRS-343

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it has raised gross proceeds of approximately $43 million through its At-the-Market facility (“ATM”) with participation based on interest received from Consonanc

Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has successfully received marketing authorization and is preparing to launch Lyfaquin ® (centhaquine), a novel resuscitative agent indicated for the treatment of p

Belite Bio, a clinical-stage biotech company, today announced positive results from two Phase 1 clinical trials in the United States and Australia for LBS-008, a First-in-Class oral small molecule Retinol Binding Protein 4 (RBP4) specific antagonist aimed to treat atrophic Age-related Macular Degeneration (Dry AMD) and Stargardt diseas

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, is pleased to announce the appointment of Mr. John Brancaccio to its Board as a Non-executive Director. Mr. Brancaccio, retired CPA, is a financial executive with extensive international and domestic experience in pharmaceutical and biote

BELKIN Laser, the Israel-based start-up offering a 1-second, non-invasive glaucoma laser treatment, announces a round B financing with an oversubscription totaling US$12.25 million.

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510 clearance and the launch of its new CRYOcheck Chromogenic Factor VIII assay in the U.S.

UCL Business (UCLB) and Apollo Therapeutics (Apollo), a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices, along with Deerfield Management Company, have completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL).

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”)